Document is current
Any future updates will be listed below
-
Authors
Raju, Gagan
Walji, Moneeza
Nemirovsky, David https://orcid.org/0009-0007-6971-1408
Devlin, Sean https://orcid.org/0000-0002-6801-720X
Goldstein, Ilan
Singh, Amandeep
Susman, Pamela
Rodriguez, Natasia https://orcid.org/0000-0003-4183-3845
Perales, Miguel-Angel https://orcid.org/0000-0002-5910-4571
Ponce, Doris M. https://orcid.org/0000-0002-9422-5766
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (5R01-HL164902-02)
- License Information
-
More Information
Article History
Received: 14 April 2025
Revised: 31 July 2025
Accepted: 15 September 2025
First Online: 4 October 2025
Competing interests
: M.A.P reports honoraria from Adicet, Allogene, Allovir, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Sanofi, Syncopation, VectivBio AG, and Vor Biopharma. He serves on DSMBs for Cidara Therapeutics and Sellas Life Sciences, and the scientific advisory board of NexImmune. He has ownership interests in NexImmune, Omeros and OrcaBio. He has received institutional research support for clinical trials from Allogene, Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. D.M.P. has served as advisory board member for Evive Biotechnology (Shanghai) Ltd; has consulted, received honorarium from, or participated in the advisory boards for Sanofi, Ceramedix, and Incyte Corporation, and received research funding from Sanofi and Incyte. The other authors have no conflicts of interest to declare.
: All methods were performed in accordance with the relevant guidelines and regulations. This analysis was approved by the Memorial Sloan Kettering Cancer Center Institutional Review Board (IRB #16-501; characterization of graft-versus-host disease following hematopoietic stem cell transplantation). Written informed consent for participation was obtained from all study participants.
